Seroatlas · Human Serome Atlas

IL33

Interleukin-33

Also known as: C9orf26, DKFZp586H0523, DVS27, IL1F11, IL33_HUMAN, NF-HEV

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
O95760
Gene
IL33
Ensembl
ENSG00000137033
Chromosome
9
Canonical length
270 aa
Protein class
Predicted intracellular proteins, Predicted secreted proteins
Subcellular location
Nucleoplasm,Vesicles
Secretome location
Secreted to blood

OverviewNCBI Gene

The protein encoded by this gene is a cytokine that binds to the IL1RL1/ST2 receptor. The encoded protein is involved in the maturation of Th2 cells and the activation of mast cells, basophils, eosinophils and natural killer cells. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2015]

Canonical amino-acid sequenceUniProt

270 residues, UniProt reviewed canonical sequence.

>O95760|IL33
     1  MKPKMKYSTN KISTAKWKNT ASKALCFKLG KSQQKAKEVC PMYFMKLRSG LMIKKEACYF
    61  RRETTKRPSL KTGRKHKRHL VLAACQQQST VECFAFGISG VQKYTRALHD SSITGISPIT
   121  EYLASLSTYN DQSITFALED ESYEIYVEDL KKDEKKDKVL LSYYESQHPS NESGDGVDGK
   181  MLMVTLSPTK DFWLHANNKE HSVELHKCEK PLPDQAFFVL HNMHSNCVSF ECKTDPGVFI
   241  GVKDNHLALI KVDSSENLCT ENILFKLSET

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against IL33 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Secreted
Secreted
Yes
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.44
Highest tissue expression
114 nTPM

Expression across tissuesHPA

Tissue

  • urinary bladder: 114 nTPM
  • placenta: 58 nTPM
  • cervix: 54 nTPM
  • lung: 51 nTPM
  • smooth muscle: 49 nTPM
  • endometrium: 47 nTPM

Single-cell type

  • respiratory basal cells: 263 nCPM
  • vascular endothelial cells: 186 nCPM
  • lymphatic endothelial cells: 132 nCPM
  • mucous neck cells: 128 nCPM
  • medullary thymic epithelial cells: 127 nCPM
  • fibroblasts: 100 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • thalamus: 15 nTPM
  • hypothalamus: 15 nTPM
  • cerebral cortex: 11 nTPM
  • basal ganglia: 11 nTPM
  • amygdala: 11 nTPM
  • hippocampal formation: 9.7 nTPM

ReferencesPubMed · IEDB

Publications for IL33 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

3 publications

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.75
gnomAD pLI
0
gnomAD missense Z
-1.03
DepMap mean gene effect
0.13
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

  • Interleukin-33
  • Interleukin 33, C-terminal
  • Interleukin 33

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads IL33 as an antibody target. Whether an autoantibody or antibody against IL33 could matter depends on whether native IL33 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

IL33 is annotated as secreted, so native IL33 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label IL33 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/IL33. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...